Liminatus Pharma, Inc. Class A Common Stock (LIMN) vs PharmaCyte Biotech, Inc. (PMCB)
A side-by-side comparison of Liminatus Pharma, Inc. Class A Common Stock and PharmaCyte Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$3.81HealthcareDelayed quote: Oct 6, 2026, 2:13 PM EDT
PMCB
PharmaCyte Biotech, Inc.
$0.43HealthcareDelayed quote: Oct 6, 2026, 2:10 PM EDT
Total return — LIMN vs PMCB
growth of $100 · dividends reinvested · last 1yLIMN -98.4% (-98.4%/yr)PMCB -67.8% (-67.8%/yr)PMCB compounded faster over this window
Log scale — wide-divergence pair
LIMN PMCB
LIMN vs PMCB: by the numbers
- •LIMN is the larger company ($5M vs $5M market cap).
Metrics side by side
Valuation
| Metric | LIMN | PMCB |
|---|---|---|
| P/B ratio | 17.02 | 0.16 |
Profitability
| Metric | LIMN | PMCB |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -4165.92% | -54.15% |
| ROIC | -225.12% | -19.51% |
Growth (annualized)
| Metric | LIMN | PMCB |
|---|---|---|
| Total return CAGR (5Y) | N/A | -33.59% |
Go deeper
Dig into the metrics
Liminatus Pharma, Inc. Class A Common Stock ROEPharmaCyte Biotech ROELiminatus Pharma, Inc. Class A Common Stock operating marginPharmaCyte Biotech operating marginLiminatus Pharma, Inc. Class A Common Stock revenue growthPharmaCyte Biotech revenue growthLiminatus Pharma, Inc. Class A Common Stock free cash flowPharmaCyte Biotech free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.